JHJuliana Mira Hernandez

Juliana Mira Hernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juliana Mira Hernandez has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression

    by Juliana Mira Hernandez, Logan R. J. Bailey, Victoria R. Salemme, Christopher Y. Ko, Erin Y. Shen, Megan Ngim, Duong T. Hoang, Melissa Corea, Julie Bossuyt, Jennifer M. Davis, et al.

    Effective treatments for heart failure with preserved ejection fraction (HFpEF) are limited. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, provides cardiovascular benefits for patients with HFpEF. SGLT2 expression is virtually absent in cardiomyocytes, hence the exact protective mechanism of empagliflozin is unclear. We aimed to study the effect of in vivo empagliflozin treatment on excitation–contraction coupling (ECC), electrophysiology, and gene transcription in a translational two-hit HFpEF mouse model that combines the obese-diabetic leptin receptor-deficient db/db mice with chronic aldosterone infusion ( db/db + Aldo). We performed morphometry, echocardiography, cardiomyocyte electrophysiology, intracellular Ca 2+ imaging, and whole-heart RNA-sequencing in empagliflozin-treated db/db + Aldo and vehicle control mice. In db/db + Aldo mice, empagliflozin (in vivo, 4 weeks) reduced the elevated plasma blood glucose (13 ± 5 mmol/L versus 23 ± 8 mmol/L) and BNP levels, prevented pulmonary congestion, and ameliorated diastolic dysfunction. However, empagliflozin did not reduce cardiac hypertrophy and obesity. In healthy control mice, empagliflozin had no functional effect. Chronic in vivo empagliflozin treatment in db/db + Aldo also normalized the changes in cardiomyocyte electrophysiology and Ca 2+ handling properties measured in the absence of empagliflozin in the perfusion solution during cell experiments, indicating a true phenotypic rescue. Differentially expressed gene clusters were identified characteristic of the db/db genotype, aldosterone, and empagliflozin treatments. Interestingly, empagliflozin did not just reverse the HFpEF-altered gene expression but shifted it further away from control to a new expression profile. We conclude that chronic in vivo empagliflozin treatment restores cardiomyocyte electrophysiological and ECC properties, ameliorates diastolic function in cardiometabolic HFpEF, and induces complex gene expression changes.


  • Top Cited Papers

    Excitation-contraction coupling, cardiomyocyte electrophysiology, and transcriptome profiles in two HFpEF murine models: etiology and sex-dependent differences

    by Bence Hegyi, Logan R. J. Bailey, Juliana Mira Hernandez, Christopher Y. Ko, Erin Y. Shen, Julie Bossuyt, Jennifer M. Davis, Donald M. Bers

    Excitation-Ca 2+ signaling-contraction coupling (ECC) mechanisms are fundamental to heart function. ECC mechanisms are differentially altered in murine models of heart failure with preserved ejection fraction (HFpEF) by dominant disease pathology and sex. Diastolic dysfunction is more pronounced in diabetic-obese HFpEF mice (worse in females) than in hypertensive-obese HFpEF mice (female sex is protective). Diabetic-obese mice and primarily hypertensive-obese HFpEF mice exhibit differential ECC alterations and largely distinctive transcription changes, providing mechanistic insights into HFpEF sub-phenogroups.


  • Open Access

    Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model

    by Juliana Mira Hernandez, Erin Y Shen, Christopher Y Ko, Zaynab Hourani, Emily R Spencer, Daria Smoliarchuk, Julie Bossuyt, Henk Granzier, Donald M Bers, Bence Hegyi

    Sex differences in heart failure with preserved ejection fraction (HFpEF) are important, but key mechanisms involved are incompletely understood. While animal models can inform about sex-dependent cellular and molecular changes, many previous pre-clinical HFpEF models have failed to recapitulate sex-dependent characteristics of human HFpEF. We tested for sex differences in HFpEF using a two-hit mouse model (leptin receptor–deficient db/db mice plus aldosterone infusion for 4 weeks; db/db + Aldo). We performed echocardiography, electrophysiology, intracellular Ca2+ imaging, and protein analysis. Female HFpEF mice exhibited more severe diastolic dysfunction in line with increased titin N2B isoform expression and PEVK element phosphorylation and reduced troponin-I phosphorylation. Female HFpEF mice had lower BNP levels than males despite similar comorbidity burden (obesity, diabetes) and cardiac hypertrophy in both sexes. Male HFpEF mice were more susceptible to cardiac alternans. Male HFpEF cardiomyocytes (vs. female) exhibited higher diastolic [Ca2+], slower Ca2+ transient decay, reduced L-type Ca2+ current, more pronounced enhancement of the late Na+ current, and increased short-term variability of action potential duration (APD). However, male and female HFpEF myocytes showed similar downregulation of inward rectifier and transient outward K+ currents, APD prolongation, and frequency of delayed afterdepolarizations. Inhibition of Ca2+/calmodulin-dependent protein kinase II (CaMKII) reversed all pathological APD changes in HFpEF in both sexes, and empagliflozin pre-treatment mimicked these effects of CaMKII inhibition. Vericiguat had only slight benefits, and these effects were larger in HFpEF females. We conclude that the db/db + Aldo pre-clinical HFpEF murine model recapitulates key sex-specific mechanisms in HFpEF and provides mechanistic insights into impaired excitation–contraction coupling and sex-dependent differential arrhythmia susceptibility in HFpEF with potential therapeutic implications. In male HFpEF myocytes, altered Ca2+ handling and electrophysiology aligned with diastolic dysfunction and arrhythmias, while worse diastolic dysfunction in females may depend more on altered myofilament properties.


  • Detection of Equus caballus Papillomavirus in Equine Aural Plaque Samples

    by Cristiana R. Bromberger, Julia Rodrigues Costa, Mariana Herman, Juliana Mira Hernandez, Lukas Garrido Albertino, Carlos Eduardo Fonseca Alves, Alexandre S. Borges, Jose P. Oliveira-Filho


  • Open Access

    Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction

    by Bence Hegyi, Juliana Mira Hernandez, Christopher Y. Ko, Junyoung Hong, Erin Y. Shen, Emily R. Spencer, Daria Smoliarchuk, Manuel F. Navedo, Donald M. Bers, Julie Bossuyt

    Background: The pathobiology of heart failure with preserved ejection fraction (HFpEF) is still poorly understood, and effective therapies remain limited. Diabetes and mineralocorticoid excess are common and important pathophysiological factors that may synergistically promote HFpEF. The authors aimed to develop a novel animal model of HFpEF that recapitulates key aspects of the complex human phenotype with multiorgan impairments. Methods and Results: The authors created a novel HFpEF model combining leptin receptor–deficient db/db mice with a 4‐week period of aldosterone infusion. The HFpEF phenotype was assessed using morphometry, echocardiography, Ca 2+ handling, and electrophysiology. The sodium‐glucose cotransporter‐2 inhibitor empagliflozin was then tested for reversing the arrhythmogenic cardiomyocyte phenotype. Continuous aldosterone infusion for 4 weeks in db/db mice induced marked diastolic dysfunction with preserved ejection fraction, cardiac hypertrophy, high levels of B‐type natriuretic peptide, and significant extracardiac comorbidities (including severe obesity, diabetes with marked hyperglycemia, pulmonary edema, and vascular dysfunction). Aldosterone or db/db alone induced only a mild diastolic dysfunction without congestion. At the cellular level, cardiomyocyte hypertrophy, prolonged Ca 2+ transient decay, and arrhythmogenic action potential remodeling (prolongation, increased short‐term variability, delayed afterdepolarizations), and enhanced late Na + current were observed in aldosterone‐treated db/db mice. All of these arrhythmogenic changes were reversed by empagliflozin pretreatment of HFpEF cardiomyocytes. Conclusions: The authors conclude that the db/db +aldosterone model may represent a distinct clinical subgroup of HFpEF that has marked hyperglycemia, obesity, and increased arrhythmia risk. This novel HFpEF model can be useful in future therapeutic testing and should provide unique opportunities to better understand disease pathobiology.


  • Equine papillomavirus detection in aural plaques by qPCR

    by Luiza Zakia1, Mariana Herman, Roberta Basso, Juliana Hernadez, Joao Araujo Jr, Alexandre Borges, Jose Oliveira-Filho


  • Open Access

    Parámetros electrocardiográficos en caballos de raza Criollo Colombiano, pacientes de un establecimiento veterinario de Antioquia, Colombia

    by Juliana Mira Hernández, Silvia Posada Arias, Cristian Alejandro Castillo Franz, Alejandro Saldarriaga Restrepo

    Las alteraciones cardiacas en los equinos no se manifiestan de una manera habitual como en otros animales; sin embargo, hay afecciones que requieren ser diagnosticadas correctamente para evaluar el desempeño atlético. Son varios los estudios publicados respecto a la utilización de métodos diagnósticos complementarios en cardiología equina, como el electrocardiograma (ECG). A pesar de ello aún no se tienen datos de referencia para el caso del Caballo Criollo Colombiano (CCC). El objetivo de este estudio fue describir los trazados electrocardiográficos de 57 CCC pacientes de la Clínica Veterinaria Lasallista, con alta previa y sin alteraciones clínicas evidentes. Los ECG fueron hechos en sistema base ápex y los animales fueron divididos en grupos de edad. Para el análisis de los datos se hizo estadística descriptiva, análisis de varianza de una vía y coeficientes de correlación. De cada grupo se obtuvieron rangos de amplitud y duración de las diferentes ondas, intervalos y segmentos. Solo se evidenció diferencia estadísticamente significativa de la duración de la onda P e intervalo PR entre grupos de edad. Existieron correlaciones de algunos de los parámetros del ECG con el peso, la edad y la frecuencia cardiaca. Con este trabajo se hace un aporte importante para aquellas ocasiones en que sea necesario recurrir al electrocardiograma para validar la información obtenida en el examen clínico o cuando se sospeche de una cardiopatía en CCC, principalmente, en el caso de arritmias.


  • Open Access

    Estudio cuantitativo de algunas medidas ecocardiográficas en caballos Criollo Colombiano

    by Silvia Posada Arias, Juliana Mira Hernández, Cristian Alejandro Castillo Franz, Mariana Vélez Mejía

    Echocardiography is considered a tool of great diagnostic value in the evaluation of cardiac anatomy and function, as it allows to non-invasively visualize aspects such as heart valve thickness and interventricular septum thickness, in addition to the possibility of measuring the dimensions of the heart chambers. This study aimed to determine some quantitative characteristics of echocardiograms taken in 60 Colombian Creole horses (CCH) of any sex, age, and weight. Images were obtained by two-dimensionally-guided M-mode echocardiography, in plane three, fourth intercostal space on the right parasternal area. The following parameters were evaluated: LVDd (left ventricular diameter in diastole), LVDs (left ventricular diameter in systole), IVSd (interventricular septum in diastole), ISVs (interventricular septum in systole), LVPWd (left ventricular posterior wall in diastole), LVPWs (left ventricular posterior wall in systole), EF (ejection fraction), FS (fractional shortening), and LVM (left ventricular mass). For data analysis, age groups were formed. Depending on data distribution, the study analyzed: mean and standard deviation, and median and percentiles (SPSS 21.0 software). This work makes an important contribution for those occasions when it is necessary to use echocardiography to validate the information obtained in clinical examination or in case of suspected heart disease in CCHs.